This study aimed to examine depth of cure (DoC), mass change, water sorption and solubility of dual-cured bulk-fill restorative materials (Surfil One and Activa) in comparison with a light-cured bulk-fill composite (Filtek One Bulk-Fill) and a resin-modified glass ionomer (Fuji II LC). Twenty specimens were prepared of each material using stainless steel molds designed with a slot (8 × 4 × 2 mm) and irradiated for either 20 or 40 s. The Vickers hardness (VHN) was measured at every 0.5 mm to assess the DoC after 24 h of storage at 37 °C. The depth of cure was reported as the depth corresponding to 80% of the maximum Vickers hardness. Disc-shaped specimens were prepared of each material ( = 5) to investigate mass change, sorption and solubility after 4 months of water storage. The data were analyzed using a two-way and one-way analysis of variance (ANOVA) followed by the Tukey post hoc test ( ≤ 0.05). Fuji II LC had the greatest DoC while Activa had the lowest. The two different irradiation times did not demonstrate a significant difference in DoC for all dual-cured materials ( > 0.05). Fuji II LC had the highest sorption while Filtek One showed the lowest. Surefil One and Fuji II LC had a negative solubility. This study concluded that dual-cured materials showed different depth of cure values despite having the same setting reaction. Both materials exhibited a high water sorption, which might jeopardize their dimensional stability and effect their clinical performance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608248 | PMC |
http://dx.doi.org/10.3390/ma16206673 | DOI Listing |
Soc Sci Med
December 2024
Division of Infectious Diseases and Global Public Health, School of Medicine, University of California, San Diego, 9500 Gilman Drive, MC 0507, La Jolla, CA, 92093, United States. Electronic address:
The lack of socio-behavioral research on stress and psychosocial experiences among research participants who undergo analytical treatment interruption (ATI) in HIV cure studies underscores a critical gap in cure science. Existing literature acknowledges mixed and potentially adverse mental health impacts of ATIs among trial participants, but empirical insights before, during, and after clinical studies are scarce. We used longitudinal in-depth interviews with 11 participants in HIV cure-related research to explore their experiences with stress, coping, and psychological well-being before, during, and after an ATI.
View Article and Find Full Text PDFFront Immunol
January 2025
Innovation & Research Department, OriCell Therapeutics Co. Ltd., Shanghai, China.
Systemic lupus erythematosus (SLE) and lupus nephritis (LN) are debilitating autoimmune disorders characterized by pathological autoantibodies production and immune dysfunction, causing chronic inflammation and multi-organ damage. Despite current treatments with antimalarial drugs, glucocorticoids, immunosuppressants, and monoclonal antibodies, a definitive cure remains elusive, highlighting an urgent need for novel therapeutic strategies. Recent studies indicate that chimeric antigen receptor T-cell (CAR-T) therapy has shown promising results in treating B-cell malignancies and may offer a significant breakthrough for non-malignant conditions like SLE.
View Article and Find Full Text PDFInt J Biol Sci
January 2025
Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China.
Sci Rep
December 2024
Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
This study explores the role of LINC00839 and its potential interaction with the miR-195-5p/cyclin E1 (CCNE1) axis in oral squamous cell carcinoma (OSCC). Using The Cancer Genome Atlas, we analyzed lncRNA, miRNA, and mRNA sequencing data for OSCC. Different online tools were applied to detect lncRNA-related miRNAs and their target mRNAs, forming a lncRNA/miRNA/mRNA axis.
View Article and Find Full Text PDFMalar J
December 2024
Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil.
Background: To eliminate malaria by 2035, Brazil must address Plasmodium vivax. Previously, first-line treatment was chloroquine plus 7-day primaquine (PQ) without glucose-6-phosphate dehydrogenase (G6PD) deficiency testing. In 2021, point-of-care quantitative G6PD testing and single-dose tafenoquine (TQ) were piloted in two municipalities.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!